Cutaneous squamous cell carcinoma manifests as a malignant growth originating from the epidermal keratinocytes and accounts for a significant clinical challenge given its propensity to evolve into aggressive and therapy-resistant disease stages. While many cSCC cases remain manageable through conventional treatments, a subset of tumors undergo a phenotypic transition that endows them with enhanced motility and invasiveness. This transition, known as epithelial-to-mesenchymal transition (EMT), marks the shift from well-differentiated, structured epithelial cells into delocalized, mesenchymal-like cells capable of systemic dissemination. The molecular events governing this transition have remained incompletely characterized until now.

The research spearheaded by Prof. Rami I. Aqeilan and colleagues reveals that WWOX, a protein previously implicated in various tumor suppressive functions, operates as a critical guardian of epidermal identity. WWOX achieves this by stabilizing p63, a master transcription factor pivotal for maintaining epithelial cell differentiation and structural integrity. Through an intricate molecular interplay, WWOX prevents the degradation of p63, thereby preserving the genetic programs essential for keratinocyte specialization and restraining cellular plasticity.

Using an integrative approach combining genetically engineered mouse models and detailed analysis of human tissue specimens, the team demonstrated that abrogation of WWOX expression precipitates a precipitous decline in p63 levels. This destabilization effectively dismantles the safeguard mechanisms that uphold cellular identity, setting the stage for EMT induction. The resulting phenotypic fluidity enables cancer cells to shed their adhesive properties, acquire migratory traits, and penetrate systemic circulation paths, ultimately facilitating metastatic colonization, particularly in vital organs like the lungs.

Further compounding the oncogenic threat, the simultaneous loss of WWOX and the well-characterized tumor suppressor p53 was shown to accelerate tumor development dramatically. Experimental models deficient in both guardians exhibited earlier tumor onset and an escalated degree of malignancy characterized by poor differentiation and heightened invasiveness compared to controls retaining functional WWOX. These findings articulate a synergistic model whereby the concurrent impairment of multiple tumor suppressive pathways drives rapid cSCC progression.

Importantly, the translational significance of this research is underscored by investigations into human clinical samples. Through tissue microarray analyses, a consistent pattern emerged demonstrating that as cSCC advances, both WWOX and p63 protein levels diminish progressively. This correlation not only reinforces the biological importance of the WWOX-p63 axis in restraining tumor aggression but also positions these proteins as valuable prognostic biomarkers. Monitoring their expression profiles could empower clinicians to predict tumor behavior more accurately and tailor therapeutic strategies accordingly.

The implications extend into therapeutic innovation, proposing the restoration or mimicking of WWOX function as a promising intervention against aggressive cSCC. Strategies aimed at bolstering WWOX expression or enhancing p63 stability could reinforce epithelial identity and prevent the EMT process, thereby curtailing metastatic spread. This novel molecular target offers an attractive avenue for drug development efforts seeking to improve outcomes for patients afflicted with advanced skin cancers.

On a molecular level, the binding interaction between WWOX and p63 appears to be essential in preserving p63’s nuclear localization and its transcriptional activity. Loss of WWOX disrupts this complex, rendering p63 vulnerable to proteasomal degradation. This mechanistic insight provides a valuable foundation for exploring small molecules or biologics that could stabilize the WWOX-p63 interaction, representing a refined, mechanism-based therapeutic modality.

The broader context of this study situates WWOX as a pivotal component of the skin’s intrinsic tumor suppressive architecture. It exemplifies the concept that cellular identity and differentiation status are not static traits but active states maintained by molecular sentinels. The failure of these sentinels unleashes a cascade of deleterious cellular reprogramming events that fuel malignancy. Such advances reveal an evolving paradigm in oncology focusing on targeting cellular plasticity as a strategy to impede cancer progression.

Prof. Aqeilan’s pioneering work not only enriches our fundamental understanding of skin cancer biology but also lays a robust framework for future clinical applications. By integrating molecular pathology, genetic modeling, and clinical specimen analyses, it bridges the gap between bench research and patient care. This multi-disciplinary approach exemplifies how deep mechanistic insights into tumor suppressor networks can translate into actionable clinical knowledge.

As cSCC incidence rises globally due to environmental and demographic factors, the urgency for novel diagnostic and therapeutic tools escalates. This study’s identification of the WWOX-p63 axis as a central regulator of tumor behavior represents a significant leap toward meeting this need. It opens exciting new directions to explore the mechanobiology of tumor differentiation states and offers a platform to design next-generation therapies aimed at reinstating the cellular programming necessary to constrain malignancy.

In conclusion, the discovery of WWOX’s critical role in maintaining epidermal identity and suppressing EMT in skin cancer illuminates a novel molecular safeguard against tumor aggressiveness and metastasis. By stabilizing p63, WWOX fortifies the cellular differentiation landscape, preventing the dangerous transformation of skin cells into invasive cancer progenitors. This foundational knowledge promises to reshape clinical approaches to cSCC, offering hope for improved prognostication, personalized treatment regimens, and ultimately better patient outcomes.

Subject of Research: Cells
Article Title: WWOX Maintains Epidermal Identity and Suppresses EMT to Prevent Aggressive Cutaneous Squamous Cell Carcinoma
News Publication Date: 15-Apr-2026
Web References: DOI: 10.1073/pnas.2534844123
References: Proceedings of the National Academy of Sciences
Image Credits: Tirza Bidnay-Mizrahi
Keywords: Skin cancer, Carcinoma, Cancer, Metastasis, Carcinogenesis

Circular RNAs (circRNAs) have emerged in recent years as pivotal regulatory elements in gene expression networks. Unlike linear RNAs, circRNAs form closed-loop structures resistant to exonucleases, enabling them to function as molecular sponges, regulators of transcription, and even templates for protein translation in some contexts. However, the direct binding of circRNAs to specific messenger RNAs (mRNAs) to regulate their stability and translation has remained elusive until now. The research conducted by Cao et al. propels the field forward by demonstrating that circMAN1A2(2,3,4,5) directly interacts with CENPB mRNA, influencing cellular behavior in a cancer-specific manner.

At the core of this study is the centromere protein B (CENPB), a critical component of the centromeric chromatin that facilitates proper chromosome segregation during mitosis. Dysregulation of CENPB has been implicated in genomic instability, a hallmark of malignant transformation. By intricately binding to CENPB mRNA, circMAN1A2(2,3,4,5) modulates the expression of this centromere-associated protein. This, in turn, affects mitotic fidelity and cell cycle progression, contributing to the unregulated proliferation characteristic of cancer cells.

The authors employed a comprehensive suite of molecular biology techniques, including RNA immunoprecipitation, RNA fluorescence in situ hybridization (FISH), and luciferase reporter assays, to elucidate the nature and consequence of the circMAN1A2(2,3,4,5)-CENPB interaction. Their data compellingly show that circMAN1A2(2,3,4,5) stabilizes CENPB mRNA, enhancing its translation by protecting it from degradation pathways. This layered regulation adds another dimension to our understanding of post-transcriptional gene control in oncogenesis.

Moreover, functional assays revealed that manipulation of circMAN1A2(2,3,4,5) levels significantly altered proliferation rates in cancer cell lines derived from various tumor types, including lung, breast, and colorectal cancers. Knockdown of the circRNA led to reduced CENPB protein expression, impaired centromere function, and a consequent decline in cellular division rates. Conversely, overexpression amplified tumorigenic phenotypes, highlighting the circRNA as a potent driver of cancer progression.

Importantly, the research pinpointed the molecular interface between circMAN1A2(2,3,4,5) and CENPB mRNA, identifying specific nucleotide sequences responsible for their interaction. This high-resolution mapping enables the possibility of designing therapeutic molecules—such as antisense oligonucleotides or small-molecule inhibitors—that can disrupt this interaction, potentially halting tumor growth at a molecular level.

The implications of this study extend beyond its immediate findings. The identification of a direct circRNA-mRNA interaction as a modulator of cell cycle dynamics introduces a previously underappreciated class of gene regulation, especially in the context of cancer. This may lead researchers to re-examine other circRNAs and their potential intra-RNA interactions, potentially uncovering a network of regulatory loops that orchestrate cellular homeostasis and pathogenesis.

The investigation also underscores the value of viewing RNA molecules not merely as intermediaries in gene expression but as active participants in regulatory circuits with tangible phenotypic outcomes. The circMAN1A2(2,3,4,5)-CENPB axis exemplifies this principle, offering a tangible nexus point between noncoding RNA biology and essential cellular machinery.

From a therapeutic standpoint, targeting circRNAs offers unique advantages. Their structural stability and often cell-type-specific expression patterns make them attractive drug targets, potentially lowering the risk of off-target effects typical of conventional therapies. Moreover, disrupting the circMAN1A2(2,3,4,5)-CENPB interaction might complement existing treatments by selectively impeding cancer cell proliferation without affecting normal cells.

Leading oncologists and molecular biologists have lauded the study for its innovation and clinical relevance. Dr. Elena Martinez, a noted expert in RNA oncology, remarked, “This research substantially shifts the paradigm of RNA-based regulation in cancer. By unveiling a direct, functionally significant interaction between a circRNA and an essential cell cycle regulator, it opens a new frontier in precision medicine.”

The study also raises intriguing questions about the evolutionary origins and conservation of such RNA-based interactions. If circRNAs can fine-tune the expression of key mitotic proteins, it suggests a sophisticated evolutionary layering of gene regulation that permits resilient control over cell division—a feature that cancer cells co-opt to fuel their unchecked growth.

Furthermore, the spatial localization of circMAN1A2(2,3,4,5) within the nucleus and cytoplasm suggests multifaceted roles in post-transcriptional regulation, potentially involving coordination with RNA-binding proteins and the broader transcriptomic landscape. Such complexity invites further exploration into the interplay between RNA species and chromatin architecture in the context of cellular proliferation.

Future research directions highlighted by the authors include the exploration of circMAN1A2(2,3,4,5)-CENPB interactions in vivo, utilizing animal models of cancer to validate therapeutic potential. Additionally, high-throughput screening for compounds that can selectively disrupt this interaction stands as an exciting prospect for drug developers aiming to target this newly identified regulatory axis.

In sum, the discovery of direct circRNA-mRNA interaction between circMAN1A2(2,3,4,5) and CENPB mRNA sets a new benchmark in RNA research, deepening our grasp of molecular oncology and signaling a promising new chapter in the fight against cancer. This study exemplifies how cutting-edge molecular tools combined with creative inquiry can illuminate the hidden layers of gene regulation with profound clinical significance, offering hope for novel, more effective cancer therapies in the near future.

Subject of Research: Direct interaction between circular RNA circMAN1A2(2,3,4,5) and CENPB mRNA and its role in regulating cell proliferation and cancer progression

Article Title: Direct circMAN1A2(2,3,4,5)-CENPB mRNA interaction regulates cell proliferation and cancer progression

Article References:
Cao, M., Yuan, G.H., Cao, S.M. et al. Direct circMAN1A2(2,3,4,5)-CENPB mRNA interaction regulates cell proliferation and cancer progression. Nat Commun 16, 8609 (2025). https://doi.org/10.1038/s41467-025-63686-7

Image Credits: AI Generated